Structural Forms of Phenprocoumon and Warfarin That Are Metabolized at the Active Site of CYP2C9
- 1 December 1999
- journal article
- research article
- Published by Elsevier in Archives of Biochemistry and Biophysics
- Vol. 372 (1) , 16-28
- https://doi.org/10.1006/abbi.1999.1468
Abstract
No abstract availableKeywords
This publication has 22 references indexed in Scilit:
- Hydroxylation of warfarin by human cDNA-expressed cytochrome P-450: a role for P-4502C9 in the etiology of (S)-warfarin-drug interactionsChemical Research in Toxicology, 1992
- Metabolic enantiomeric interactions: The inhibition of human (S)-warfarin-7-hydroxylase by (R)-warfarinChirality, 1991
- The effect of sulfinpyrazone on the disposition of pseudoracemic phenprocoumon in humansClinical Pharmacology & Therapeutics, 1987
- The preferred solution conformation of warfarin at the active site of cytochrome P-450 based on the CD spectra in octanol/water model systemJournal of Medicinal Chemistry, 1984
- Lack of effect of cimetidine on action of phenprocoumonEuropean Journal of Clinical Pharmacology, 1982
- Conformations of selected 3-substituted 4-hydroxycoumarins in solution by nuclear magnetic resonance. Warfarin and phenprocoumonJournal of Medicinal Chemistry, 1978
- Anomalous chiroptical properties of warfarin and phenprocoumonJournal of Medicinal Chemistry, 1978
- Structure of warfarin in solutionJournal of Medicinal Chemistry, 1977
- The enantiomers of phenprocoumon: Pharmacodynamic and pharmacokinetic studiesClinical Pharmacology & Therapeutics, 1976
- PHENPROCOUMON, DIPHENADIONE, WARFARIN AND BISHYDROXYCOUMARINThe Lancet Healthy Longevity, 1964